anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For this study, it was planned to recruit 40 patients who would have FOB in the ICU of Abant İzzet Baysal University Anesthesia department. All intubated patients over 18 years of age who do not meet the exclusion criteria will be included. Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered. Volume-controlled ventilation modes will be preferred during FOB. The pre-trade-inspired FiO2 will be increased to 100%. During the procedure, mean blood pressure, heart rate, oxygen saturation, respiratory rate, CVP, airway pressure, and BIS will be closely monitored. Enteral feeding will be discontinued at least 6 hours before the procedure. At the end of the procedure, the endotracheal tube position will be checked.

FOB will be performed using mobile bronchoscopy (Storz FB; 5.0 mm outer diameter). All patients will be monitored with BIS (Bispectral Index A-2000, Aspect Medical Systems, Netherlands) to measure the depth of sedation. Patients will be randomly divided into two groups by an anesthesiologist blinded to the study. Propofol will not be given to Group I after midazolam, while propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure. Patients under the age of 18, pregnancy, using sedative drugs in the last 24 hours, hypersensitivity to the drugs used in the study, severe cardiac disorder (EF: \< 40), those who increase the QT interval (quinidine, lithium, procainamide, amiodarone, sotalol, phenothiazine, tricyclic Those who use antidepressants, disopyramide) or reducing (digitals) drugs, affecting QT such as hypomagnesemia- hypocalcemia - hypo or hyperthermia - hypo or hypercalcemia - hyperkalemia - hyper or hypothyroidism - myocarditis - mitral heart prolapse, etc. will be excluded from the study.

Patients will be randomly divided into 2 equal groups using the closed envelope method. Oral and written consent will be obtained from the first-degree relatives of all patients. All patients will be monitored with BIS to measure the depth of sedation. Age, weight - height, gender, medications used, comorbidities, hospitalization diagnosis, and duration of the procedure will be recorded for both groups. In addition, systolic blood pressure, diastolic blood pressure, mean blood pressure, heart rate, SpO2, BIS, respiratory rate, CVP, and airway pressure will be noted before and after the procedure of the first, fifth, tenth, and fifteenth minute. P wave dispersion, OTc, and OTd values will be calculated according to the max and min wavelengths as the primary outcomes.
INTRODUCTION: The occurrence of death from acute pulmonary embolism (PE) is often linked to right ventricular (RV) failure, arising from an imbalance between RV systolic function and heightened RV afterload. In our study, we posited that an echocardiographic ratio derived from this disparity [RV systolic function assessed by tricuspid annular plane systolic excursion (TAPSE) divided by pulmonary arterial systolic pressure (PASP)] could offer superior predictive value for adverse outcomes compared to individual measurements of TAPSE and PASP alone.
METHODS: We conducted a retrospective analysis using data from a University Hospital Centre spanning from 2017 to 2023. All individuals with confirmed PE and a formal transthoracic echocardiogram within 7 days of diagnosis were included. The primary endpoint was a composite outcome of death, hemodynamic deterioration needing introduction of inotropes or thrombolysis within 30 days. Secondary endpoints included 6 months all-cause mortality and onset of right-sided heart failure.
RESULTS: Thirty-eight patients were included. Mean age was 58 ±15 years old. A male predominance was noted: 23 male patients (60.5%) and 15 female patients (39.5%). Eight patients met the primary composite endpoint while nine patients met the secondary composite endpoint. In multivariate analysis, the TAPSE/PASP ratio was independently associated with the primary outcome (OR=2.77, 95% CI 1.101-10.23, P=0.042). A TAPSE/PASP ratio <0.3 was independently associated with the secondary outcome (OR=3.07, 95% CI 1.185-10.18, P=0.034).
CONCLUSION: This study suggests that a combined echocardiographic ratio of RV function to afterload is effective in predicting adverse outcomes in acute PE.
In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg/day. This dose is approximately 30 times and 2.5 times the maximum recommended human dose on a mg/kg and mg/m2 basis, respectively. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown.

Methylphenidate did not cause any increase in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 22 times and 4 times the maximum recommended human dose on a mg/kg and mg/m2 basis, respectively.

Methylphenidate was not mutagenic in the in vitro Ames reverse mutation assay or in the in vitro mouse lymphoma cell forward mutation assay. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary (CHO) cells. The genotoxic potential of methylphenidate has not been evaluated in an in vivo assay.

Usage in Pregnancy 

Adequate animal reproduction studies to establish safe use of Methylphenidate Hydrochloride during pregnancy have not been conducted. However, in a recently conducted study, methylphenidate has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day, which is approximately 167 times and 78 times the maximum recommended human dose on a mg/kg and a mg/m2 basis, respectively. In rats, teratogenic effects were not seen when the drug was given in doses of 75 mg/kg/day, which is approximately 62.5 and 13.5 times the maximum recommended human dose on a mg/kg and a mg/m2 basis, respectively. Therefore, until more information is available, methylphenidate should not be prescribed for women of childbearing age unless, in the opinion of the physician, the potential benefits outweigh the possible risks.
FIELD: medicine, gastroenterology. SUBSTANCE: the method deals with a rectal ozone-oxygenous mixture injection at 100 cm 3  volume at an increase to 500-600 cm 3  during the next procedures. Ozone concentration is 6-30 mcg/ml against a type of intestinal motor system. In case of a spastic intestine and constipation - 6-10 mcg/ml, but at an atonic intestine and diarrhea - 20-30 mcg/ml. Mixture is retained in the intestine for 10-30 min. Procedures should be carried out twice or thrice weekly, 8-10 procedures altogether. EFFECT: restored motor system of intestine, normalized bacterial flora, increased efficiency of therapy. 4 cl, 2 ex
Any solid tumor in the presence of liver metastasis indicates poor prognosis, short overall survival, immunotherapy combination with anti-tumor angiogenesis agents have some curative effection according to recent studies. It seems there has been clinical evidence to improve the immune microenvironment of the tumor, while in the case of only liver metastasis, the tumor's characteristics may not be consistent with other tumors. This study was to investigate the efficacy and safety of such patients by combining Apatinib and SHR-1210. This study will include approximately 20 patients with solid tumors with only liver metastases (progression after first-line treatment). The investigators will evaluate the efficacy and safety of Apatinib combined with SHR-1210 in these patients. If possible we would check the patients' ctDNA and some infection factors.
Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
PURPOSE: To obtain a medicine composition synergistically enhanced in the effect and capable of shortening a period for curing a wound by disposing an antihistamine for blocking H-1 and/or H-2 receptors on a porous solid carrier for covering the wound. CONSTITUTION: An antihistamine (e.g. cimetidine, ranitidine) for blocking H-1 and/or H-2 receptors is disposed in an amount of 0.1-15wt.%, preferably 0.1-5.0wt.%, on a proper porous solid carrier (e.g. dextrin particle polymer crosslinked with epichlorohydrin or cyclodextrin) useful for covering a wound or an injury. A polyurethane sponge sheet, a plain cotton weave sheet, etc., is preferably used as the solid carrier. The composition is prepared by treating the porous solid carrier with a solution containing the active ingredient in an amount of 0.1-30wt.%, preferably 0.3-10wt.%.
FIELD: medicine. SUBSTANCE: method involves administering two systemic polychemotherapy courses with 3 weeks long pause between the courses. The following treatment schedule is suggested. Metotrexate is intravenously administered at a dose of 5mg/m 2  as bolus dose from the first to the fifth day. Carboplatin is administered at a dose of 50mg/m 2  as 45 min long intravenous infusion from the first to the fifth day. 5-fluorouracyl is administered at a dose of   as 3 h long intravenous infusion from the first to the fifth day. Surgical intervention is carried out 3 weeks later, after the polychemotherapy course being over. Cisplatin is administered at a dose of 15mg/m 2  during the operation. EFFECT: enhanced effectiveness in treating III stage stomach cancer cases.
A reduced gloss, single phase cosmetic composition that is soft and water resistant below a selected temperature (e.g., 43 ℃). The composition is durable, stain and peel resistant, and oil resistant. The compositions according to the invention comprise specific combinations of acrylate/VA copolymer, acrylate copolymer and HDI/trimethylol hexyl lactone crosslinked polymer// silica in a cosmetically acceptable matrix or delivery vehicle. The composition according to the invention is hydrophilic before application but will dry to a transparent hydrophobic film. The dried film is easily removed when scrubbed with water above a certain temperature, but not easily removed with water below that temperature. The composition is easy to manufacture, soft and comfortable, and is suitable for skin and hair.
Lactobacillus delbrueckii subsp. lactis CIDCA 133 is a health-promoting bacterium that can alleviate gut inflammation and improve the epithelial barrier in a mouse model of mucositis. Despite these beneficial effects, the protective potential of this strain in other inflammation models, such as inflammatory bowel disease, remains unexplored. Herein, we examined for the first time the efficacy of Lactobacillus delbrueckii CIDCA 133 incorporated into a fermented milk formulation in the recovery of inflammation, epithelial damage, and restoration of gut microbiota in mice with dextran sulfate sodium-induced colitis. Oral administration of Lactobacillus delbrueckii CIDCA 133 fermented milk relieved colitis by decreasing levels of inflammatory factors (myeloperoxidase, N-acetyl-β-D-glucosaminidase, toll-like receptor 2, nuclear factor-κB, interleukins 10 and 6, and tumor necrosis factor), secretory immunoglobulin A levels, and intestinal paracellular permeability. This immunobiotic also modulated the expression of tight junction proteins (zonulin and occludin) and the activation of short-chain fatty acids-related receptors (G-protein coupled receptors 43 and 109A). Colonic protection was effectively associated with acetate production and restoration of gut microbiota composition. Treatment with Lactobacillus delbrueckii CIDCA 133 fermented milk increased the abundance of Firmicutes members (Lactobacillus genus) while decreasing the abundance of Proteobacteria (Helicobacter genus) and Bacteroidetes members (Bacteroides genus). These promising outcomes influenced the mice's mucosal healing, colon length, body weight, and disease activity index, demonstrating that this immunobiotic could be explored as an alternative approach for managing inflammatory bowel disease.
The invention concerns a wide range of diseases and conditions, including cancers. The invention provides a probe for detection of such a disease or condition. The probe is able to distinguish between functional P2X7 receptors and non-functional P2X7 receptors. The probe can do this in various ways, one of which is detecting change in relation to binding of adenosine triphosphate (ATP) to the receptors. The invention also provides a method for detecting the disease or condition, using the probe. The invention extends to treatment of the disease or condition, using an antibody, or an epitope capable of generating the antibody, which can distinguish between functional and non-functional P2X7 receptors and bind to the non-functional receptors. Methods of treatment, pharmaceutical compositions and use of the probe and antibody are also included.
The invention discloses a formed body for a dental department and a resin material for a dental department. The material of the formed body for a dental department is resin material. The resin material comprises 65%-90% of polypropylene by weight, 7%-25% of polyethylene or ethylene alpha olefin copolymer by weight, 0.01%-2% of magnesium stearate by weight, 0.001%-1% of one or two of titanium oxide and ferric oxide, and 0.0001%-1% of pigment. The total content of said components is above 90%. Experimental results show that the formed body for a dental department and the resin material for a dental department disclosed in the invention are proper in bending strength, suitable for human hardness, difficult for miscellaneous bacteria breeding and high in safety. There is no resin anaphylactic reaction. Bisphenol A cannot be dissolved.
Thyroidectomy is one of the most frequently performed operations in endocrine surgery. Results are generally excellent, and morbidity and mortality are usually negligible. The operation requires proper identification of important structures such as the recurrent laryngeal nerve (RLN) and the parathyroid glands. Meticulous dissection and exhaustive hemostasis are important to ensure a dry field and to avoid inadvertent damage to the adjacent structures. The two most common techniques for hemostasis are suture ligatures and electrocoagulation. The use of electrocoagulation (EC) to control bleeding has the potential risk of injuring the surrounding structures from lateral dispersion of heat. New haemostatic techniques have been developed with the advent of laparoscopic surgery. Among other things, ultrasound instruments have been used for the dissection, division and coagulation of vessels and other tissue. Previous studies in Thyroidectomy observed a clinically and economically significant reduction in operating time with no increase in the complication rate when the Harmonic device has been used. The aim of the present clinical trial is to evaluate potential advantages of a new Harmonic device (FOCUS), developed especially for Thyroid procedures, in the use of HS in thyroidectomies when compared with EC in terms of operative time, number of ligatures, QoL, blood loss, pain intensity at the surgical site, amount of drainage, and complications, including the incidence of RLN palsy and hypoparathyroidism.
The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
Surgical excision is the most effective treatment of skin carcinomas (basal cell carcinoma or squamous cell carcinoma). Preoperative assessment of tumoral margins plays a decisive role for a successful result. The aim of this work was to evaluate the possibility that hyperspectral imaging could become a valuable tool in solving this problem. Hyperspectral images of 11 histologically diagnosed carcinomas (six basal cell carcinomas and five squamous cell carcinomas) were acquired prior clinical evaluation and surgical excision. The hyperspectral data were then analyzed using a newly developed method for delineating skin cancer tumor margins. This proposed method is based on a segmentation process of the hyperspectral images into regions with similar spectral and spatial features, followed by a machine learning-based data classification process resulting in the generation of classification maps illustrating tumor margins. The Spectral Angle Mapper classifier was used in the data classification process using approximately 37% of the segments as the training sample, the rest being used for testing. The receiver operating characteristic was used as the method for evaluating the performance of the proposed method and the area under the curve as a metric. The results revealed that the performance of the method was very good, with median AUC values of 0.8014 for SCCs, 0.8924 for BCCs, and 0.8930 for normal skin. With AUC values above 0.89 for all types of tissue, the method was considered to have performed very well. In conclusion, hyperspectral imaging can become an objective aid in the preoperative evaluation of carcinoma margins.
The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
SUBSYS may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions ( 7)] . Monitor these patients for signs of hypotension after initiating or titrating the dosage of SUBSYS. In patients with circulatory shock, SUBSYS may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of SUBSYS in patients with circulatory shock.
The rate of diabetes in Saskatchewan is among the highest of all Canadian provinces with a prevalence of 8.5% in 2015 with an expected rise to 11.1% in 2025. Diabetic foot ulcers (DFU) are a common complication and the leading cause of lower limb amputation worldwide. Treatment for DFU include casts, braces, crutches and walkers to remove pressure (offload) from the ulcer. These interventions, when not rejected, foster a sedentary lifestyle which negatively impacts function and quality of life. Also, crutches and walkers may increase risk of ulceration of the sound foot as the arms are often not strong enough to support the body weight when stepping.

The wheeled knee walkers (WKW) is a relatively new walking aid that allows total offloading of one foot, requires less physical exertion, and is more stable than crutches or walkers. The purpose of this research is to determine if a WKW would improve wound healing, quality of life, and physical function while decreasing the risk of sound foot ulceration in people with DFU. To explore these objectives we will recruit people with DFU who are under the care of a vascular surgeon, perform standardized baseline measures for each objective, provide a WKW to half of the participants and then re-evaluate all objectives at 6 and 12 weeks. The results will help guide treatment and inform decision making to optimize care. Further, the project will establish an interdisciplinary collaborative research program for future projects to improve health and advance knowledge.
Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INV1 04B)) identified in Streptococcus pneumoniae isolate INV1 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141 that are absent from Streptococcus pneumoniae isolate INV104. The polypeptides, including fragments and variants thereof, may be used in immunogenic compositions for prophylactic or therapeutic immunization against Streptococcus pneumoniae. The polypeptides are also disclosed to be used in compositions useful for the production of antibodies and immunostimulants. Also presented are methods of inhibiting Streptococcus pneumoniae, methods of treating Streptococcus pneumoniae infection, methods of identifying inhibitors of Streptococcus pneumoniae and methods for diagnosing/detecting Streptococcus pneumoniae infection.
A system (10) for managing inventory of blood component collection soft goods in a blood component collection facility is disclosed. The sysem comprises an operator identifier a blood collection instrument, system computer and a data interface. The blood component collection instrument (20a) collects a blood component from the blood component donor. The system computer (48) is operably connected to the blood component collection instrument and runs a blood component collection application for at least a portion of a blood component collection process. The system computer (48) is in data communication with a system database (62) having a blood component collection soft good inventory. The interface (44b) includes a reader and iks operably connected to the system computer and receives the operator identifier (90) and transmits the operator identifier to the system computer. The reader also receives separate input of the blood omponent soft good identifier and transmits the blood component soft good identifier to the system database.
The slow released anticancer injection consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The effective anticancer component is the composition of fotemustine, nimostine, carmustine, bendamustine, etc. The slow releasing supplementary material is polylactic acid and its copolymer, polyethylene glycol-polylactic acid copolymer, EVAc, etc. The .suspending agent is carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent. The present invention has lowered systemic reaction and raised local concentration for 30-50 days, and may be used alone effectively and in enhancing the curative effect of chemotherapy, radiotherapy and other non-operative treatment.